{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:22Z","timestamp":1790244622507,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1097\/md.0000000000005076","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T13:23:24Z","timestamp":1475760204000},"page":"e5076","source":"Crossref","is-referenced-by-count":17,"title":["Drug\u2013drug interactions with imatinib"],"prefix":"10.1097","volume":"95","author":[{"given":"Isabelle","family":"R\u00e9coch\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bourrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chebane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-61-20210309","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R3-61-20210309","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","article-title":"The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib","volume":"27","author":"Oostendorp","year":"2009","journal-title":"Invest New Drugs"},{"key":"R4-61-20210309","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"R5-61-20210309","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mayocp.2012.10.020","article-title":"Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents","volume":"88","author":"Bowlin","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"R6-61-20210309","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"R8-61-20210309","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","article-title":"Pharmacovigilance in practice","volume":"6","author":"Spreux","year":"1999","journal-title":"Transfus Clin Biol"},{"key":"R9-61-20210309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R10-61-20210309","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"R11-61-20210309","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"R13-61-20210309","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pds.1912","article-title":"Pharmacoepidemiological research using French reimbursement databases: yes we can!","volume":"19","author":"Martin-Latry","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R14-61-20210309","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2515\/therapie\/2015027","article-title":"Use in France of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI","volume":"70","author":"Chaignot","year":"2015","journal-title":"Therapie"},{"key":"R15-61-20210309","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/sim.4780100408","article-title":"Using a claims database to investigate drug-induced Stevens\u2013Johnson syndrome","volume":"10","author":"Strom","year":"1991","journal-title":"Stat Med"},{"key":"R16-61-20210309","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/pds.1717","article-title":"Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study","volume":"18","author":"Noize","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-61-20210309","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2007.2002","article-title":"NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines","volume":"5","author":"Demetri","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"R19-61-20210309","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure.","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R20-61-20210309","first-page":"469a","article-title":"A Phase II study of STI571 in adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia on accelerated phase","volume":"96","author":"Talpaz","year":"2000","journal-title":"Blood"},{"key":"R21-61-20210309","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2165\/00003088-199120010-00003","article-title":"Clinical pharmacology of omeprazole","volume":"20","author":"Howden","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"R22-61-20210309","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2036.2005.02528.x","article-title":"Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod","volume":"22","author":"Tougas","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-61-20210309","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"R24-61-20210309","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","article-title":"The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res"},{"key":"R25-61-20210309","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R26-61-20210309","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","article-title":"Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?","volume":"37","author":"von Mehren","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R27-61-20210309","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2125.2009.03466.x","article-title":"Effect of a proton pump inhibitor on the pharmacokinetics of imatinib","volume":"68","author":"Egorin","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R28-61-20210309","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00280-007-0562-0","article-title":"Dermatitis after suspected imatinib\u2013levothyroxine interaction in a patient with gastrointestinal stromal tumor","volume":"61","author":"Cholongitas","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R29-61-20210309","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R30-61-20210309","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","article-title":"On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios","volume":"21","author":"van der Heijden","year":"2002","journal-title":"Stat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:35:06Z","timestamp":1620959706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201610040-00061"}},"subtitle":["An observational study"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":26,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005076","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}